Form 4 Filing for Beam Therapeutics Inc.

This filing details stock transactions by John M. Evans, CEO and Director of Beam Therapeutics Inc. On June 29, 2026, Evans exercised stock options and acquired 25,000 shares of common stock at prices of $0.67 and $1.03, totaling 18,663 and 6,337 shares respectively. He also sold 13,421 shares at a weighted average of $35.1336 and 11,579 shares at a weighted average of $35.9119. On June 30, 2026, Evans acquired an additional 25,000 shares at $1.03 through option exercise. He subsequently sold 23,100 shares at a weighted average of $34.2633 and 1,900 shares at a weighted average of $34.8437. These transactions were conducted under a Rule 10b5-1 trading plan. Following these transactions, Evans directly holds 1,047,205 shares. Additionally, 103,000 shares are held indirectly through the John M. Evans, III 2018 Irrevocable Trust.